Common Names: Chinese ephedra, Chinese joint-fir
ESP, a polysaccharide, has strong therapeutic effects on rheumatoid arthritis. The gut microbiota enzymes and derivatives play a role in the inflammatory immune response in RA. Important for potential treatment development.
GBJ, a herbal formula, reduces HFD-induced cardiac apoptosis in obese mice. GBJ reverses pro-apoptotic protein levels and improves mitochondrial function, showing promise for cardiovascular health.
Mahuang and Wuweizi herbs, commonly used in traditional Chinese medicine for respiratory symptoms, work together to improve efficacy in treating cough and asthma. The mechanism against asthma is still unknown.
BHQJ is a traditional Chinese herbal remedy made from 7 plants. It effectively treats cough asthma and reduces airway inflammation.
The study explores the potential of Ephedra przewalskii extract as a treatment for infectious diseases. While E. sinica extract is used in traditional medicines, it has side effects. E. przewalskii extract is ephedrine-free but lacks sufficient evidence for its antiviral efficacy.
This review analyzed the therapeutic effects of natural products on obesity. Several natural products, including coffee, green tea, garlic, and others, showed anti-obesity effects. Further research is needed for clinical use.
Obesity is influenced by the balance of gut bacteria. Herbal medicine shows promise in treating obesity, but more research is needed to understand how it works.
Many herbal medicines, including Lianhua Qingwen capsules and Houttuynia cordata, have shown promise in treating COVID-19 by targeting the angiotensin converting enzyme 2 (ACE2) receptor which allows the virus to enter host cells. This study summarizes a range of herbal formulas, single herbs, and active ingredients that exhibit a high affinity for ACE2 and warrant further investigation. Such research could lead to the discovery of new drugs to fight COVID-19.
This study examines the potential of Ephedra sinica polysaccharide (ESP) to mitigate lung damage caused by PM2.5 pollution, which is linked to asthma and other respiratory diseases.
The combination of traditional Chinese medicine and western medication appears to be an effective treatment strategy for COVID-19 patients in China. This review focuses on the relationship between COVID-19 and gut microbiota and the potential impact of traditional Chinese medicine on gut microbiota in treating COVID-19 patients. Available data suggests that gut microbiota dysbiosis occurs in COVID-19 patients, and intervention can improve patient's clinical condition. Certain traditional Chinese medicines have been proven to be safe and effective for treating COVID-19, and they have a positive impact on gut microbiota, immunity, and angiotensin converting enzyme 2. The hypothesis of gut microbiota-mediated traditional Chinese medicine treatment of COVID-19 is proposed, but more clinical trials and basic experiments are needed to confirm this hypothesis.
Qing Fei Pai Du Tang (QFPDT), a Chinese medicine formula consisting of 21 herbs, has been reported to be effective in treating COVID-19. It has been shown to prevent the progression of mild cases and shorten hospital stays. The formula has been recommended in China's Clinical Practice Guideline on COVID-19. Basic scientific studies have identified QFPDT's anti-oxidation, immuno-modulation, and antiviral mechanisms, including cytokine storm prevention and angiotensin converting enzyme 2 (ACE2) receptor binding regulation. QFPDT's multi-target mechanisms for treating viral infections in general and COVID-19 in particular were validated. While large-scale clinical studies of QFPDT are ongoing, real-world data can be used to explore integrative treatment options, including herb-drug interactions.